scholarly journals Exploring the Diversity of the Marine Environment for New Anti-cancer Compounds

2021 ◽  
Vol 7 ◽  
Author(s):  
Divya L. Dayanidhi ◽  
Beatrice C. Thomas ◽  
Joshua S. Osterberg ◽  
Mallissa Vuong ◽  
Giselle Vargas ◽  
...  
Keyword(s):  
Terrestrial Ecosystems ◽  
Cancer Therapies ◽  
Clinical Use ◽  
Marine Environments ◽  
Cancer Drugs ◽  
Hallmarks Of Cancer ◽  
Natural Sources ◽  
Anti Cancer ◽  
Almost All ◽  
Untapped Resource

Marine ecosystems contain over 80% of the world’s biodiversity, and many of these organisms have evolved unique adaptations enabling survival in diverse and challenging environments. The biodiversity within the world’s oceans is a virtually untapped resource for the isolation and development of novel compounds, treatments, and solutions to combat human disease. In particular, while over half of our anti-cancer drugs are derived from natural sources, almost all of these are from terrestrial ecosystems. Yet, even from the limited analyses to date, a number of marine-derived anti-cancer compounds have been approved for clinical use, and several others are currently in clinical trials. Here, we review the current suite of marine-derived anti-cancer drugs, with a focus on how these compounds act upon the hallmarks of cancer. We highlight potential marine environments and species that could yield compounds with unique mechanisms. Continued exploration of marine environments, along with the characterization and screening of their inhabitants for unique bioactive chemicals, could prove fruitful in the hunt for novel anti-cancer therapies.

scholarly journals Anticancer Agents from Diverse Natural Sources

2014 ◽  
Vol 9 (11) ◽  
pp. 1934578X1400901 ◽  
Author(s):  
Jabeena Khazir ◽  
Darren L. Riley ◽  
Lynne A. Pilcher ◽  
Pieter De-Maayer ◽  
Bilal Ahmad Mir
Keyword(s):  
Clinical Trials ◽  
Natural Products ◽  
Anticancer Agents ◽  
Marine Organisms ◽  
New Drugs ◽  
Human Diseases ◽  
Cancer Drugs ◽  
Natural Sources ◽  
Anti Cancer ◽  
Ancient Times

This review attempts to portray the discovery and development of anticancer agents/drugs from diverse natural sources. Natural molecules from these natural sources including plants, microbes and marine organisms have been the basis of treatment of human diseases since the ancient times. Compounds derived from nature have been important sources of new drugs and also serve as templates for synthetic modification. Many successful anti-cancer drugs currently in use are naturally derived or their analogues and many more are under clinical trials. This review aims to highlight the invaluable role that natural products have played, and continue to play, in the discovery of anticancer agents.

scholarly journals Targeting Cytoprotective Autophagy to Enhance Anticancer Therapies

2021 ◽  
Vol 11 ◽  
Author(s):  
Malina Xiao ◽  
Alice Benoit ◽  
Meriem Hasmim ◽  
Caroline Duhem ◽  
Guillaume Vogin ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Current Knowledge ◽  
Therapeutic Benefit ◽  
Cancer Therapies ◽  
Cancer Resistance ◽  
Tumor Resistance ◽  
Anti Cancer ◽  
Almost All ◽  
The Impact

Autophagy is a highly regulated multi-step process that occurs at the basal level in almost all cells. Although the deregulation of the autophagy process has been described in several pathologies, the role of autophagy in cancer as a cytoprotective mechanism is currently well established and supported by experimental and clinical evidence. Our understanding of the molecular mechanism of the autophagy process has largely contributed to defining how we can harness this process to improve the benefit of cancer therapies. While the role of autophagy in tumor resistance to chemotherapy is extensively documented, emerging data point toward autophagy as a mechanism of cancer resistance to radiotherapy, targeted therapy, and immunotherapy. Therefore, manipulating autophagy has emerged as a promising strategy to overcome tumor resistance to various anti-cancer therapies, and autophagy modulators are currently evaluated in combination therapies in several clinical trials. In this review, we will summarize our current knowledge of the impact of genetically and pharmacologically modulating autophagy genes and proteins, involved in the different steps of the autophagy process, on the therapeutic benefit of various cancer therapies. We will also briefly discuss the challenges and limitations to developing potent and selective autophagy inhibitors that could be used in ongoing clinical trials.

Overview on Anticancer Drug Design and Development

2018 ◽  
Vol 25 (15) ◽  
pp. 1704-1719 ◽  
Author(s):  
Sureyya Olgen
Keyword(s):  
Kinase Inhibitors ◽  
Molecular Design ◽  
Resistance Mechanisms ◽  
Cancer Drug ◽  
Computational Techniques ◽  
Cancer Therapies ◽  
Cancer Drugs ◽  
Design Strategies ◽  
Advantages And Disadvantages ◽  
Anti Cancer

Background: Many impediments of current anti-cancer therapies have urged scientists to discover new agents. As a result of growing spectrums of new targets and strategies and recent biological and biotechnological progresses, many anti-cancer agents such as monoclonal antibodies, small molecule tyrosine kinase inhibitors and epigenetic drugs have been reached to clinical trials. Objectives: This review helps to understand the rationale for the development of inhibitors against major targets such as cell growth, proliferation, survival, angiogenesis and recent targets such as proteasome, heat shock proteins, and epigenetics. Methods: Recent approaches of the target-based anti-cancer drug developments were highlighted to giving some examples from approved agents. Many factors, such as metabolic change, hypoxia, cancer precursors and cancer resistant cells, and their effect on drug resistance mechanisms were discussed. The impacts of advanced computational techniques to identify targets of cancer and designing more selective inhibitors were explained. Results: Contributions of recent techniques such as a network analysis, the precise modes of action and computational methodologies especially simulation of bio-molecular processes to clarify targets, mechanism actions and reasons of lack of efficacy of anti-cancer drugs have been explained. The relationship between the several mechanisms and molecular design strategies has been discussed. Conclusion: This review provides an overview of important targets and design strategies of anti-cancer drugs, advantages and disadvantages of these methods and evaluation of some currently used anticancer targets in clinical studies.

scholarly journals Improving Cancer Immunotherapy by Targeting the Hypoxic Tumor Microenvironment: New Opportunities and Challenges

Cells ◽  
2019 ◽  
Vol 8 (9) ◽  
pp. 1083 ◽  
Author(s):  
Muhammad Zaeem Noman ◽  
Meriem Hasmim ◽  
Audrey Lequeux ◽  
Malina Xiao ◽  
Caroline Duhem ◽  
...  
Keyword(s):  
Tumor Microenvironment ◽  
Molecular Mechanisms ◽  
Cancer Therapies ◽  
Hallmarks Of Cancer ◽  
The Past ◽  
Therapeutic Value ◽  
Anti Cancer ◽  
Microenvironmental Factors ◽  
Hypoxic Tumor ◽  
Insight Into

Initially believed to be a disease of deregulated cellular and genetic expression, cancer is now also considered a disease of the tumor microenvironment. Over the past two decades, significant and rapid progress has been made to understand the complexity of the tumor microenvironment and its contribution to shaping the response to various anti-cancer therapies, including immunotherapy. Nevertheless, it has become clear that the tumor microenvironment is one of the main hallmarks of cancer. Therefore, a major challenge is to identify key druggable factors and pathways in the tumor microenvironment that can be manipulated to improve the efficacy of current cancer therapies. Among the different tumor microenvironmental factors, this review will focus on hypoxia as a key process that evolved in the tumor microenvironment. We will briefly describe our current understanding of the molecular mechanisms by which hypoxia negatively affects tumor immunity and shapes the anti-tumor immune response. We believe that such understanding will provide insight into the therapeutic value of targeting hypoxia and assist in the design of innovative combination approaches to improve the efficacy of current cancer therapies, including immunotherapy.

scholarly journals Precision Cardio-Oncology: Use of Mechanistic Pharmacokinetic and Pharmacodynamic Modeling to Predict Cardiotoxicities of Anti-Cancer Drugs

2022 ◽  
Vol 11 ◽  
Author(s):  
Hai-ni Wen ◽  
Chen-yu Wang ◽  
Jin-meng Li ◽  
Zheng Jiao
Keyword(s):  
Patient Survival ◽  
Survival Rates ◽  
Pharmacodynamic Modeling ◽  
Cancer Therapies ◽  
Cancer Drugs ◽  
Cancer Treatments ◽  
Disease States ◽  
Chronic Effects ◽  
Anti Cancer ◽  
Important Approach

The cardiotoxicity of anti-cancer drugs presents as a challenge to both clinicians and patients. Significant advances in cancer treatments have improved patient survival rates, but have also led to the chronic effects of anti-cancer therapies becoming more prominent. Additionally, it is difficult to clinically predict the occurrence of cardiovascular toxicities given that they can be transient or irreversible, with large between-subject variabilities. Further, cardiotoxicities present a range of different symptoms and pathophysiological mechanisms. These notwithstanding, mechanistic pharmacokinetic (PK) and pharmacodynamic (PD) modeling offers an important approach to predict cardiotoxicities and offering precise cardio-oncological care. Efforts have been made to integrate the structures of physiological and pharmacological networks into PK-PD modeling to the end of predicting cardiotoxicities based on clinical evaluation as well as individual variabilities, such as protein expression, and physiological changes under different disease states. Thus, this review aims to report recent progress in the use of PK-PD modeling to predict cardiovascular toxicities, as well as its application in anti-cancer therapies.

scholarly journals Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Henry Gerdes ◽  
Pedro Casado ◽  
Arran Dokal ◽  
Maruan Hijazi ◽  
Nosheen Akhtar ◽  
...  
Keyword(s):  
Machine Learning ◽  
Mean Squared Error ◽  
Distance Metrics ◽  
Cancer Therapies ◽  
Cancer Drugs ◽  
Cellular Models ◽  
Independent Verification ◽  
Squared Error ◽  
Wide Range ◽  
Anti Cancer

AbstractArtificial intelligence and machine learning (ML) promise to transform cancer therapies by accurately predicting the most appropriate therapies to treat individual patients. Here, we present an approach, named Drug Ranking Using ML (DRUML), which uses omics data to produce ordered lists of >400 drugs based on their anti-proliferative efficacy in cancer cells. To reduce noise and increase predictive robustness, instead of individual features, DRUML uses internally normalized distance metrics of drug response as features for ML model generation. DRUML is trained using in-house proteomics and phosphoproteomics data derived from 48 cell lines, and it is verified with data comprised of 53 cellular models from 12 independent laboratories. We show that DRUML predicts drug responses in independent verification datasets with low error (mean squared error < 0.1 and mean Spearman’s rank 0.7). In addition, we demonstrate that DRUML predictions of cytarabine sensitivity in clinical leukemia samples are prognostic of patient survival (Log rank p < 0.005). Our results indicate that DRUML accurately ranks anti-cancer drugs by their efficacy across a wide range of pathologies.

A Case of Malignant Melanoma Treated with a Combination of Anti-Cancer Drugs and Biological Response Modifiers.

1993 ◽  
Vol 55 (1) ◽  
pp. 43-46
Author(s):  
Jun YOSHIDA ◽  
Juichiro NAKAYAMA ◽  
Nobuyuki SHIMIZU ◽  
Shonosuke NAGAE ◽  
Yoshiaki HORI
Keyword(s):  
Malignant Melanoma ◽  
Biological Response ◽  
Biological Response Modifiers ◽  
Cancer Drugs ◽  
Anti Cancer

ANTICANCER EFFECT OF UVARIA GENUS

2014 ◽  
pp. 98-101
Author(s):  
Thi Bich Hien Le ◽  
Viet Duc Ho ◽  
Thi Hoai Nguyen
Keyword(s):  
Biological Activities ◽  
Current Trend ◽  
Healthcare Systems ◽  
Chemical Compositions ◽  
Cancer Therapies ◽  
Pharmacological Effects ◽  
Anticancer Effect ◽  
Anti Cancer ◽  
Tropical Areas ◽  
Cancer Activity

Nowadays, cancer treatment has been a big challenge to healthcare systems. Most of clinical anti-cancer therapies are toxic and cause adverse effects to human body. Therefore, current trend in science is seeking and screening of natural compounds which possess antineoplastic activities to utilize in treatment. Uvaria L. - Annonaceae includes approximately 175 species spreading over tropical areas of Asia, Australia, Africa and America. Studies on chemical compositions and pharmacological effects of Uvaria showed that several compound classes in this genus such as alkaloid, flavonoid, cyclohexen derivaties, acetogenin, steroid, terpenoid, etc. indicate considerable biological activities, for example anti-tumor, anti-cancer, antibacterial, antifungal, antioxidant, etc. Specifically, anti-cancer activity of fractions of extract and pure isolated compounds stands out for cytotoxicity against many cancer cell lines. This study provides an overview of anti-cancer activity of Uvaria and suggests a potential for further studies on seeking and developing novel anti-cancer compounds. Key words: Anti-cancer, Uvaria.

Sign in / Sign up

Export Citation Format

Share Document